- Home
- CSTL
as 11-22-2024 4:00pm EST
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FRIENDSWOOD |
| Market Cap: | 946.1M | IPO Year: | 2019 |
| Target Price: | $37.57 | AVG Volume (30 days): | 457.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.97 - $35.84 | Next Earning Date: | 11-04-2024 |
| Revenue: | $311,878,000 | Revenue Growth: | 62.43% |
| Revenue Growth (this year): | 49.05% | Revenue Growth (next year): | -17.41% |
Stock Insider Trading Activity of Castle Biosciences Inc. (CSTL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Stokes Frank | CSTL | Chief Financial Officer | Nov 15 '24 | Sell | $30.14 | 6,923 | $207,217.21 | 31,623 | |
| Juvenal Tobin W | CSTL | Chief Commercial Officer | Nov 5 '24 | Sell | $35.56 | 3,507 | $124,708.92 | 54,178 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Nov 4 '24 | Sell | $32.84 | 5,127 | $166,819.96 | 6,465 | |
| BRADBURY DANIEL | CSTL | Director | Nov 1 '24 | Sell | $34.72 | 7,867 | $273,251.23 | 4,562 | |
| Juvenal Tobin W | CSTL | Chief Commercial Officer | Nov 1 '24 | Sell | $35.39 | 3,100 | $109,709.00 | 54,178 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Oct 14 '24 | Sell | $32.27 | 5,127 | $165,463.67 | 6,465 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Oct 8 '24 | Sell | $30.27 | 2,562 | $77,549.18 | 6,465 | |
| BRADBURY DANIEL | CSTL | Director | Oct 7 '24 | Sell | $29.44 | 7,867 | $231,628.08 | 4,562 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Oct 4 '24 | Sell | $28.73 | 2,565 | $73,702.71 | 6,465 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Sep 16 '24 | Sell | $30.97 | 5,127 | $158,793.44 | 6,465 |
Latest Castle Biosciences Inc. News
CSTL Breaking Stock News: Dive into CSTL Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
Business Wire
3 days ago
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
Zacks
4 days ago
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
Business Wire
4 days ago
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
Zacks
5 days ago
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
Zacks
9 days ago
RNA Stock Hits Record High on Entering the Cardiac Disease Space
Zacks
11 days ago
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
Simply Wall St.
11 days ago
Castle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings Suggest
Compare CSTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CSTL Castle Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.